Immune profiling of pediatric solid tumors.

Abstract

Pediatric cancers, particularly high-risk solid tumors, urgently need effective and specific therapies. Their outlook has not appreciably improved in decades. Immunotherapies such as immune checkpoint inhibitors offer much promise, but most are only approved for use in adults. Though several hundred clinical trials have tested immune-based approaches in childhood cancers, few have been guided by biomarkers or clinical-grade assays developed to predict patient response and, ultimately, to help select those most likely to benefit. There is extensive evidence in adults to show that immune profiling has substantial predictive value, but few studies focus on childhood tumors, because of the relatively small disease population and restricted use of immune-based therapies. For instance, only one published study has retrospectively examined the immune profiles of pediatric brain tumors after immunotherapy. Furthermore, application and integration of advanced multiplex techniques has been extremely limited. Here, we review the current status of immune profiling of pediatric solid tumors, with emphasis on tumor types that represent enormous unmet clinical need, primarily in the context of immune checkpoint inhibitor therapy. Translating optimized and informative immune profiling into standard practice and access to personalized combination therapy will be critical if childhood cancers are to be treated effectively and affordably.

• Authors: Rachael L Terry, Deborah Meyran, David S Ziegler, Michelle Haber, Paul G Ekert, Joseph A Trapani, Paul J Neeson
• Journal: The Journal of clinical investigation (J Clin Invest) Vol. 130 Issue 7 Pg. 3391-3402 (07 01 2020) ISSN: 1558-8238 [Electronic] United States
• PMID: 32538896 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Topics

• Adult
• Brain Neoplasms (classification, immunology, pathology, therapy)
• Child
• Humans
• Immunotherapy